Differential behavioural effect of quinpirole in neuroleptic-pretreated rats - role of alpha(1)-adrenoceptor.
This paper presents the effect of 14-day intraperitoneal (i.p.) neuroleptic treatment on the behavioural response of Wistar rats to (-)-quinpirole hydrochloride (3 mg/kg, i.p.) administered 24 h after the last neuroleptic dose. Chlorpromazine hydrochloride (10 mg/kg), haloperidol (2 mg/kg) or (+/-)-sulpiride (100 mg/kg) increased the effect of quinpirole; however, there were qualitative and quantitative differences between the neuroleptics. Chlorpromazine and haloperidol, but not sulpiride, pretreatment enhanced quinpirole-induced locomotor hyperactivity. Prazosin (0.5 mg/kg, i.p. ) given to chlorpromazine-treated rats 1 h before quinpirole attenuated the quinpirole-induced hyperlocomotion. In chlorpromazine-pretreated rats, quinpirole elicited defensive aggressive behaviour with vocalization, copulatory attempts, intense rearing and head-down sniffing. When prazosin was given before quinpirole, head-down sniffing and object-directed oral activity were mainly observed. In haloperidol-pretreated rats, quinpirole induced intense head-down sniffing, rearing, grooming and object-directed oral activity. In sulpiride-pretreated rats, quinpirole induced intense head-down sniffing, grooming and object-directed oral activity. The results of the study suggest that differences in the behavioural expression of dopamine D(2) receptor supersensitivity induced by neuroleptics may be, at least in part, caused by concurrent stimulation of alpha(1)-adrenoceptors.
Obuchowicz
E
E
Department of Clinical Pharmacology, Silesian University School of Medicine, 18 Medyków Street, Katowice, Poland.
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D011224:Prazosin / Q000494:pharmacology; D019257:Quinpirole / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology; D012965:Sodium Chloride / Q000494:pharmacology; D013469:Sulpiride / Q000494:pharmacology
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018340:Receptors, Adrenergic, alpha-1; D019257:Quinpirole; D012965:Sodium Chloride; D013469:Sulpiride; D006220:Haloperidol; D002746:Chlorpromazine; D011224:Prazosin